The first collaboration will develop selective formyl peptide receptor 2 (FPR2) agonists for the treatment of ischaemia reperfusion injury. The second collaboration will develop positive allosteric modulators (PAMs) and agonists of melanocortin receptor type 3 (MC3) for treatment of joint disease.
This project will focus on developing novel modulators of the second galanin receptor subtype (GalR2) for neuropathic pain, a major medical and economic burden, and a complication in several other diseases such as diabetes.
The collaboration will focus on the development of monoclonal antibodies that can be commercialized as drugs to control infection and treat diseases. MRC Technology will humanize mouse antibodies that are created by Mount Sinai’s Center for Therapeutic Antibody Discovery (CTAD).
The newly-launched research grant terms approval service, provided the MS Society with the first review. As an expert in commercialising intellectual property, MRC Technology is ideally placed to advise on how best to ensure that grant terms and conditions are comprehensive, meet industry standards, and have the best chance of supporting the development of novel treatments.
Phosphate Therapeutics has acquired the global rights to PT20, a novel Phase 2 ready phosphate binder for the treatment of hyperphosphataemia. The PT20 programme was initially supported by funding from the MRC’s Development Gap Fund and this deal was negotiated by MRC Technology on behalf of MRC. At the same time funding of up to €10.5m has been secured from Inventages Venture Capital (Inventages) to complete the Phase 2 development of PT20.
Collaboration aims to develop orally available small molecule TrkA antagonists for treatment of chronic intractable pain.
MRC Technology’s Therapeutic Antibody Group and The University of Aberdeen will work together on a project to…
Aptuscan, a spin out company based on research carried out by Paul Ko Ferrigno whilst working at…